Additionally, incorporating EGFR inhibitors has emerged as a promising strategy to counteract resistance, particularly in colorectal cancer, where B-RAF inhibition alone leads to feedback activation of EGFR and MAPK signaling [39,61]. This evidence concerns the gene EGFR and colorectal cancer.